Company intelligence / Profile preview
AviadoBio
London (Canary Wharf), United Kingdomaviadobio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
AviadoBio entered the clinic in April 2024 with the world's first-in-human intrathalamic delivered gene therapy (AVB-101) for frontotemporal dementia. The ASPIRE-FTD clinical trial is currently evaluating AVB-101 in people with frontotemporal dementia with GRN mutations[3][6].
- Therapeutic areas
- Neurology
- Modalities
- Gene therapyGene silencers
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Astellas (exclusive option and license agreement for AVB-101)
Beyond the preview
Go deeper on AviadoBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AviadoBio.